RxDoctor Payments DataLook up a doctor →

Samuel Hunter

Neurology · Spring Hill, TNNPI 1093808107

Payments from drug & device makers

$2,933,632in general payments, 2019–2025

Across 1,127 payments — averaging $2603.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$667K
  • AbbVie$434K
  • Bristol Myers Squibb$401K
  • Novartis$235K
  • EMD Serono, Inc.$232K
  • Biogen$211K
  • plus $753K from 36 others
$25,023in research payments, 2019–2025

Across 41 payments — averaging $610.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$13K
  • Novartis$12K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi205$666,963
AbbVie61$433,982
Bristol Myers Squibb58$401,482
Novartis121$235,107
EMD Serono, Inc.152$231,660
Biogen89$211,272
Alkermes, Inc.29$160,266
Janssen Research & Development, LLC35$140,941
E.r. Squibb & Sons, L.L.C.14$109,676
F. Hoffmann-la Roche AG9$56,631
Johnson & Johnson(2 entities)64$50,535
AstraZeneca(2 entities)76$47,176
Adamas Pharmaceuticals, Inc.15$43,226
Genentech, Inc.8$39,757
Amgen(2 entities)34$37,413
Genentech USA, Inc.43$27,528
Mallinckrodt Hospital Products Inc.11$13,864
Mallinckrodt Enterprises LLC14$12,857
Banner Life Sciences, LLC3$4,587
Greenwich Biosciences, Inc.1$3,094
TG Therapeutics, Inc.33$2,849
Janssen Scientific Affairs, LLC1$1,320
Ipsen Biopharmaceuticals, Inc9$181
Vanda Pharmaceuticals Inc.7$174
Actelion Pharmaceuticals, Ltd2$139
Sanofi-aventis U.S. LLC3$138
Lilly USA, LLC3$132
Tanabe Pharma America, Inc.2$114
ANI Pharmaceuticals, Inc.2$100
Avanir Pharmaceuticals, Inc.5$98
Lundbeck LLC5$86
Cycle Pharmaceuticals Inc2$70
Teva Pharmaceuticals USA, Inc.2$30
Argenx US, Inc.1$25
CSL Behring1$24
Biohaven Pharmaceuticals, Inc.1$23
Takeda Pharmaceuticals U.S.A., Inc.1$23
Jazz Pharmaceuticals Inc.1$20
Vertex1$19
Eisai Inc.1$19
Scilex Pharmaceuticals Inc.1$16
Vertical Pharmaceuticals, LLC1$14

How this compares

$2,933,632 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$20,643
Medicare patients
73
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Spring Hill

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →